Pillar Biosciences
in the News

Stay informed with the latest news, press releases, and media coverage from Pillar Biosciences. This section features company milestones, industry partnerships, product announcements, and highlights of our impact across the precision diagnostics landscape.

Pillar Biosciences Announce Automated NGS Library Preparation Method on Hamilton Microlab STAR to Accelerate Myeloproliferative Neoplasm Research

October 28, 2025

Pillar Biosciences to Showcase NGS Research Insights at 2025 AMP Meeting

October 22, 2025

Fast, reliable solutions for oncology workflows: Illumina and Pillar team up at ESMO 2025 to showcase a powerful combination of NGS tests

October 17, 2025

Pillar Biosciences and Platomics Announce Collaboration to Support EU Clinical Labs with Documentation of NGS Workflows

September 5, 2025

Pillar Biosciences Raises $34.5M in Funding

Pillar Biosciences Receives CMS Coverage for FDA Approved oncoReveal® CDx Pan-Cancer Solid tumor IVD Kit

Pillar Biosciences and Hamilton Company Announce NGS Application Development and Co-Marketing Agreement

February 18, 2025

Reflecting on 2024: A Year of Growth, Innovation, and Partnership at Pillar Biosciences

January 12, 2025

Pillar Biosciences Enters into Strategic Licensing Agreement for MSK’s OncoKB™ Precision Medicine Knowledgebase

January 7, 2025

Cancer Centers Look to New NGS-Based ‘Frankenpanel’ to Get Fast Info on Clinically Actionable Genes

December 17, 2024

Pillar Biosciences to Present Impactful Research Data at 2024 Association for Molecular Pathology (AMP) Annual Meeting

November 14, 2024

Pillar Biosciences Receives CPT® Code for FDA Approved oncoReveal™ CDx Pan-Cancer Solid Tumor IVD Kit

October 24, 2024

Pillar Biosciences Announces Expansion of NGS Commercial Partnership with Illumina

October 16, 2024

Pillar Biosciences Partners with AstraZeneca to Help Accelerate Access to Liquid Biopsy Testing

September 10, 2024

Pillar Biosciences Launches oncoReveal™ Nexus To Help Accelerate the Delivery of Targeted Therapy

August 27, 2024

Pillar Biosciences’ FDA Approved Solid Tumor NGS Kit oncoReveal™ CDx Launched at Molecular Pathology Laboratory Network, Inc.

Pillar Biosciences oncoReveal™ CDx pan-cancer solid tumor IVD now FDA approved for general tumor profiling on the Illumina MiSeq™Dx System

Pillar Biosciences to Present at NYBIO | NYSE Life Science Company Showcase on December 14th

December 7, 2023

Pillar Biosciences to Present New Scientific Data at Association for Molecular Pathology Annual Meeting

November 8, 2023

Beckman Coulter Life Sciences and Pillar Biosciences Announce NGS Application Development Pipeline for the Biomek NGeniuS System

November 7, 2023

Pillar Biosciences Launches oncoReveal Core LBx, an NGS Kit to Enable Localized Liquid Biopsy-Based Tumor Profiling

September 19, 2023

Illumina and Pillar Biosciences Partner to Improve Access to Personalized Cancer Treatment Options

Pillar Biosciences and KeyGene Enter into Licensing Agreement

Pillar Biosciences Receives College of American Pathologists (CAP) Accreditation

February 7, 2023

Exquisitely Platinum-Sensitive Triple-Negative Breast Cancer, Time for BRCA Methylation Testing?

November 18, 2022

Beckman Coulter Life Sciences and Pillar Biosciences Sign Application Development Agreement for the Biomek NGeniuS System

October 31, 2022

Pillar Biosciences to Participate in the 2022 Wells Fargo Healthcare Conference

August 31, 2022

Pillar Biosciences Receives China National Medical Products Administration (NMPA) Approval for oncoReveal™ Dx Colon Cancer Assay

August 22, 2022

Pillar Biosciences to Participate in the 2022 UBS Genomics 2.0 and MedTech Innovations Summit

Pillar Biosciences Announces U.S. Food and Drug Administration Acceptance of Premarket Approval (PMA) Supplement Application for Pan-cancer oncoReveal™ CDx

Pillar Biosciences Strengthens Leadership Team with Appointment of Vincent Ricci as Chief Financial Officer

Pillar Biosciences Announces Online Publication of Data in the Journal of Clinical Oncology

Pillar Biosciences Presents New Clinical Validation Data Confirming the Accuracy of its oncoReveal™ Dx Lung & Colon Cancer Assay in Detecting Clinically Relevant Variants

Pillar Biosciences Expands Leadership Team with Appointment of Daniel Harma as Chief Commercial Officer and Christa Adkins as General Counsel

Pillar Biosciences to Present at the BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference

February 10, 2022

Pillar Biosciences Receives CLIA Certification for its Next-Generation Sequencing Clinical Laboratory

January 6, 2022

Pillar Biosciences seeks to make precision medicine a first-line therapy for cancer patients

November 2, 2021

Pillar Biosciences to Collaborate with Labcorp on Precision Genomic Cancer Testing Using Next-Generation Sequencing

October 14, 2021

Pillar Biosciences Announces Appointment of Randy Pritchard as Chief Executive Officer

September 1, 2021

XING Genomic Services receives NATA accreditation for Pillar Biosciences HRD Gene Panel Enabling Cost-Effective PARPi-response Prediction

August 18, 2021

Pillar Biosciences Receives Premarket Approval from FDA for its oncoReveal™ Dx Lung and Colon Cancer Assay

Pillar Biosciences appoints Dr. Eric Lai to its Board of Directors

Pillar Biosciences and PierianDx Announce Partnership to Support Precision Cancer Care

October 15, 2020

Pillar Biosciences welcomes new independent board member Robert Forrester

October 5, 2020

NextGen Omics UK Virtual Conference

September 25, 2020

This small academic lab ramped up in-house NGS testing despite limited resources, and you can too

Finding flexibility in a resource limited world: Online presentation

The complexity of the NGS process, compounded by sample processing, results in unique challenges for clinical oncology laboratories

Pillar NGS panels go global with increased platform versatility

November 4, 2019

5 reasons to go custom with your next sequencing panel

October 28, 2019

Garbage in, greatness out: making the most of FFPE samples

October 9, 2019

Meet SLIMamp: Columbia University’s new tumor sequencing workhorse

October 2, 2019

Columbia University Medical Center Receives Conditional Approval by the New York State Department of Health for a Custom Pillar Biosciences NGS Panel

Pillar Biosciences Enters Strategic Partnership With China Biotech Services Holdings to Deliver Precision Diagnostics to Markets in Asia

January 10, 2019

Workshop: Single-vial amplification-based NGS to interrogate variants in tumors with limited diagnostic material

November 14, 2018

Pillar Biosciences Announces Issuance of China and U.S. Patents Covering SLIMamp™ Technology

December 11, 2017

Pillar Biosciences announces ISO 13485:2016 Certification

November 29, 2017

Pillar Biosciences to Collaborate with Illumina on Next-Generation Sequencing Based In Vitro Diagnostics Development

October 26, 2017

ORI Healthcare Fund Invests in Pillar Biosciences

Presentations

Posters

Publications

Want to be the first to know about new and exciting news at Pillar Biosciences?

Sign up for our mailing list here